Quarterly report pursuant to Section 13 or 15(d)

Liquidity and Going Concern - Additional Information (Detail)

v3.7.0.1
Liquidity and Going Concern - Additional Information (Detail) - USD ($)
Mar. 31, 2017
Dec. 31, 2016
Liquidity and Going Concern [Line Items]    
Cash $ 55,241,957 $ 29,355,528
AstraZeneca [Member]    
Liquidity and Going Concern [Line Items]    
Receivable from counter party $ 57,500,000